Our live projects reflect our belief in 'learning by doing'. We work closely with global blue-chip companies and international organisations to ensure you tackle projects which have real impact. Live projects provide a rare opportunity to explore new industries and test new approaches.
For each project you will be supported by academic mentors to ensure you are getting the most out of your project and to promote a rigorous academic approach.
Our programme includes two real-time projects:
- A week-long group project where you work in small teams consulting for a major organisation
- An individual project where you focus on a business challenge faced by you or your organisation
Cambridge Judge Business School has built strong relationships with a wide range of multinational corporations and FTSE 100 companies, including:
- CSCP Zhongnuo
- Saatchi & Saatchi
- Santa Rita (Vineyards)
- Voyager Spirit
During the last two years we’ve worked with companies across the world including Dano Oilfield Services in Beijing, Venari Resources in Texas, Enso Health in Mumbai and Raiffesen Bank in Vienna.
The Executive MBA Individual Projects can be about any practical aspect of business or management. They give participants the opportunity to explore an area of particular interest, and allow for a deeper, more critical and more reflective exploration of their chosen topic.
Our participants' Individual Projects represent a contribution to new knowledge, and some of these, shown here, are subsequently published as papers for academic, practitioner, or policy audiences:
Why large public projects fail
Kjetil Holgeid, Managing Director, Nordic Technology Lead Health & Public Service
Kjetil Holgeid developed his Individual Project, entitled "A reflection on why large public projects fail", into a book chapter. Working with his supervisor Dr Mark Thompson (who became a co-author on the chapter), Kjetil highlighted the importance of contextual issues in contributing to the "spectacular" failure rates of large projects in the public sector. By studying these contextual issues related to project failure, the authors developed a new framework - the Contextual IT Project Framework - which takes greater account of "hyper-emergent" characteristics that often cannot be predicted at the outset.
Read the full chapter (pdf, 218KB) (from "The Governance of Large-Scale Projects - Linking Citizens and the State", The Hertie School of Governance and the Journal for Political Consulting and Policy Advice, 2013)
The flaw of averages in US corporate income taxes
Michael Salama, Lead Tax Counsel and VP of Corporate Tax, The Walt Disney Company
This study explains how Jensen's Inequality exists in various income tax contexts and discusses why representing uncertain numbers with average values will on average produce a faulty result.
Read the full article (pdf, 237KB) (from The Virginia Tax Review's Spring 2011 issue)
What's not to like: smart money shies away from social
Daniel Ganev, Director, Karoll Capital Management
Research has found that social media is a proven tool for companies to achieve strategic goals, including higher profitability and valuations. Yet the adoption of social media by asset managers is rather low compared to other industries. For a business where brand awareness, networking and client communications are key sources of competitive advantage, the reluctance to embrace social is a problem. Why does "smart money" shy away from social?
Read the full article (pdf, 125KB) (from Funds Europe magazine's June 2013 issue)
The financial ecosystem and early-stage biotechnology firms
Dr Gergely Toth, CEO and President, Gardedam Therapeutics
The study uncovers distinct paradoxes in the funding ecosystem of early stage biotechs, which suggest that the present ecosystem is not well aligned with the interests of these biotechnology firms and the biotechnology industry; specifically it neglects strategic disease burden needs. The study recommends that increase in funding and improvement of current financing approaches for early-stage biotechnology companies by more government and big pharmaceutical company participation should take place, because the cost of capital for these two organisations is substantially lower compared to private corporate investors such as venture capitalist.
Read the full article in the Journal of Commercial Biotechnology